Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 15, 2024.

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2023 = ×
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×
Dec 31, 2021 = ×
Sep 30, 2021 = ×
Jun 30, 2021 = ×
Mar 31, 2021 = ×
Dec 31, 2020 = ×
Sep 30, 2020 = ×
Jun 30, 2020 = ×
Mar 31, 2020 = ×
Dec 31, 2019 = ×
Sep 30, 2019 = ×
Jun 30, 2019 = ×
Mar 31, 2019 = ×

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

The primary reason for the decrease in return on equity ratio (ROE) over Q4 2023 is the decrease in financial leverage ratio.


Three-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2023 = × ×
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×
Dec 31, 2021 = × ×
Sep 30, 2021 = × ×
Jun 30, 2021 = × ×
Mar 31, 2021 = × ×
Dec 31, 2020 = × ×
Sep 30, 2020 = × ×
Jun 30, 2020 = × ×
Mar 31, 2020 = × ×
Dec 31, 2019 = × ×
Sep 30, 2019 = × ×
Jun 30, 2019 = × ×
Mar 31, 2019 = × ×

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

The primary reason for the decrease in return on equity ratio (ROE) over Q4 2023 is the decrease in efficiency measured by asset turnover ratio.


Five-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2023 = × × × ×
Sep 30, 2023 = × × × ×
Jun 30, 2023 = × × × ×
Mar 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Sep 30, 2022 = × × × ×
Jun 30, 2022 = × × × ×
Mar 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×
Sep 30, 2021 = × × × ×
Jun 30, 2021 = × × × ×
Mar 31, 2021 = × × × ×
Dec 31, 2020 = × × × ×
Sep 30, 2020 = × × × ×
Jun 30, 2020 = × × × ×
Mar 31, 2020 = × × × ×
Dec 31, 2019 = × × × ×
Sep 30, 2019 = × × × ×
Jun 30, 2019 = × × × ×
Mar 31, 2019 = × × × ×

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

The primary reason for the decrease in return on equity ratio (ROE) over Q4 2023 is the decrease in efficiency measured by asset turnover ratio.


Two-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2023 = ×
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×
Dec 31, 2021 = ×
Sep 30, 2021 = ×
Jun 30, 2021 = ×
Mar 31, 2021 = ×
Dec 31, 2020 = ×
Sep 30, 2020 = ×
Jun 30, 2020 = ×
Mar 31, 2020 = ×
Dec 31, 2019 = ×
Sep 30, 2019 = ×
Jun 30, 2019 = ×
Mar 31, 2019 = ×

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

The primary reason for the decrease in return on assets ratio (ROA) over Q4 2023 is the decrease in asset turnover ratio.


Four-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2023 = × × ×
Sep 30, 2023 = × × ×
Jun 30, 2023 = × × ×
Mar 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Sep 30, 2022 = × × ×
Jun 30, 2022 = × × ×
Mar 31, 2022 = × × ×
Dec 31, 2021 = × × ×
Sep 30, 2021 = × × ×
Jun 30, 2021 = × × ×
Mar 31, 2021 = × × ×
Dec 31, 2020 = × × ×
Sep 30, 2020 = × × ×
Jun 30, 2020 = × × ×
Mar 31, 2020 = × × ×
Dec 31, 2019 = × × ×
Sep 30, 2019 = × × ×
Jun 30, 2019 = × × ×
Mar 31, 2019 = × × ×

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

The primary reason for the decrease in return on assets ratio (ROA) over Q4 2023 is the decrease in efficiency measured by asset turnover ratio.


Disaggregation of Net Profit Margin

Vertex Pharmaceuticals Inc., decomposition of net profit margin ratio (quarterly data)

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2023 = × ×
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×
Dec 31, 2021 = × ×
Sep 30, 2021 = × ×
Jun 30, 2021 = × ×
Mar 31, 2021 = × ×
Dec 31, 2020 = × ×
Sep 30, 2020 = × ×
Jun 30, 2020 = × ×
Mar 31, 2020 = × ×
Dec 31, 2019 = × ×
Sep 30, 2019 = × ×
Jun 30, 2019 = × ×
Mar 31, 2019 = × ×

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

The primary reason for the increase in net profit margin ratio over Q4 2023 is the increase in effect of taxes measured by tax burden ratio.